Publication Name	World Journal of Gastroenterology
Manuscript ID	2232
Country	Italy

Received	2013-02-07 20:54
Peer-Review Started	2013-02-10 21:21
To Make the First Decision	2013-03-18 18:59
Return for Revision	2013-03-25 20:44
Revised	2013-03-25 23:33
Second Decision	2013-04-03 15:23
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-04-04 03:34
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-04-24 16:01
Publish the Manuscript Online	2013-05-02 10:59

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Letter to the Editor
Article Title	Role of molecular analysis in the adjuvant treatment of gastrointestinal stromal tumours: It is time to define it
Manuscript Source	Invited Manuscript
All Author List	Margherita Nannini, Maria A Pantaleo and Guido Biasco
Funding Agency and Grant Number
Corresponding Author	Dr. Margherita Nannini, Department of Hematology and Oncological Sciences "LA Seragnoli" , Sant'Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. maggie.nannini@gmail.com
Key Words	Gastrointestinal stromal tumours; Platelet-derived growth factor receptor alpha; KIT; Wild-type; Molecular analysis; Imatinib; Adjuvant treatment
Core Tip	Sendur et al pointed out the attention on the importance of mutational analysis for adjuvant treatment of gastrointestinal stromal tumor (GIST). In particular, they suggested that the optimal dose and duration of adjuvant therapy could be defined by the mutational status of the primary disease. This topic represents a big challenge in GIST's management by now, because even if the molecular analysis is strictly recommended in the work-flow of all GIST, its role in the adjuvant setting remains still unsettled due to the lack of prospective large clinical trials. In particular we pointed out the attention on the KIT/platelet-derived growth factor receptor alpha wild type GIST, that are extremely heterogeneous both in clinical and molecular background, making difficult their management also in the adjuvant setting. Our comment would underline the importance of centralised laboratories, given the increasingly important role of molecular analysis in the work-flow of all GIST, and the need of retrospective analyses for subgroups population stratified for the mutational status from the available studies in the adjuvant setting, in order to define the role of mutational analysis in choosing the optimal dose and duration of adjuvant therapy.
Publish Date	2013-05-02 10:59
Citation	Nannini M, Pantaleo MA, Biasco G. Role of molecular analysis in the adjuvant treatment of gastrointestinal stromal tumours: It is time to define it. World J Gastroenterol 2013; 19(16): 2583-2586
URL	http://www.wjgnet.com/1007-9327/full/v19/i16/2583.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i16.2583

Full Article (PDF)	WJG-19-2583.pdf
Manuscript File	2232-Review.doc
Answering Reviewers	2232-Answering reviewers.doc
Copyright License Agreement	2232-Copyright Assignment.PDF
Peer-review Report	2232-Peer reviews.pdf
Scientific Editor Work List	2232-Scientific editor work list.doc